Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Cash machine

Qantas Airways
3:27pm
February 27, 2025
QAN reported an in line 1H25 result with Jetstar’s strong growth, better than expected FCF and a large fully franked dividend (first since COVID) the highlights. Whilst QAN’s operating environment remains favourable, we continue to see the stock fully valued at current levels. HOLD maintained.

A nice 2Q25 turn around

Clearview Wealth
3:27pm
February 27, 2025
Overall we saw this result as delivering well after a tough 1Q25. The key highlight being claims normalising in 2Q25, and all key FY26 targets being re-affirmed (with a lift to the gross premium target). We increase our CVW FY25F/FY26F EPS by 2%-16% on higher top-line growth and improved claims assumptions. Our PT increases to A$0.65. On face value, the claims spike CVW saw in 1Q25 looks like a blip rather than a trend. We see significant upside in CVW at current levels and maintain our ADD call.

Back on the throttle

Motorcycle Holdings
3:27pm
February 27, 2025
MTO continued its recent momentum through to the end of 1H25, delivering an improved result, with sales +12%; EBITDA +20%; and NPAT up 43%. The result was ~4% ahead of our sales and ~7% ahead of our NPAT expectations – a positive start to the year after a challenging FY24. Strong sales growth within Mojo (+21%) and New/Used MCs (+11%) drove the result, as sales growth accelerated towards the end of the CY24. The group remains cautiously optimistic for another positive 2H25 result, with some momentum carrying into January. We are encouraged by the ongoing recovery of the business and view MTO as well positioned for a turn in the cycle. We continue to view the valuation as undemanding on 8x FY25F PE and an 8% yield. Add.

1H25 and outlook disappoints

Helloworld
3:27pm
February 27, 2025
HLO’s 1H25 result materially missed our forecast and consensus expectations. EBITDA fell 20% on the pcp, despite the 1H25 having an additional month of the acquisitions. The highlight was the large interim dividend given HLO’s strong balance sheet. FY25 EBITDA guidance was also significantly below consensus estimates. Guidance implies a stronger 2H vs 1H and HLO highlighted its solid forward bookings. We have made large downgrades to our forecasts. Despite HLO’s undemanding trading multiples, we maintain a Hold rating until there is a clearer picture on its outlook and earnings growth resumes.

Margin improvement coming

Monash IVF
3:27pm
February 27, 2025
MVF’s 1H25 result was in line with guidance provided, with NPAT up 5.5% to $15.8m. Short term volatility in industry cycle volumes does not alter our view of the strong structural growth drivers that we think will underpin growth in the IVF industry. We expect MVF to continue to gain market share in Australia, leverage infrastructure and patient management system to drive higher margins and continue to expand in South East Asia, which we think will drive growth in earnings over the next few years. We have lowered our NPAT in line with guidance provided. We have decreased our target price to $1.45 (from $1.50) driven by earnings revisions. ADD retained.

1H inline- EU jettison? Only one piece of the puzzle

Ramsay Health Care
3:27pm
February 27, 2025
1H underlying operating profit was pre-released so unsurprisingly in line, driven by low single digit admissions growth and indexation gains. However, earnings were a mixed bag, with growth in Australia and UK acute hospitals, while Elysium and EU went backwards on going inflationary pressures. While it is a welcome sign “strategic options” are actively being pursued for the EU division, with possible divestment in the air, new management flagged a multi-year transformation is required in remaining business and it continues to run a ruler across all divisions, making it difficult at this early stage to assess if adjustments in operational strategy will have the desired impact. We adjust FY25-27 earnings, with our price target decreasing to A$37.10. Hold.

Things starting to come together

Coles Group
3:27pm
February 27, 2025
COL’s 1H25 result was above expectations with the performance of the core Supermarkets division the key standout. Key positives: COL delivered $157m of Simplify & Save to Invest (SSI) cost savings during the half, taking cumulative savings to ~$400m over the past 18 months; COL invested significantly into resources to take advantage of industrial action that impacted operations at Woolworths (WOW), which yielded an extra $20m in EBIT during the half. Key negatives: Liquor EBIT was below (-12%) our forecast, although the market saw some slight recovery in November and December; Cash realisation at 69% was low due to the timing of payments but should revert to ~100% for the full year. We lift FY25-27F underlying EBIT by between 3-4%. Our target price increases to $20.90 (from $17.95) on the back of updates to earnings estimates and a roll-forward of our model to FY26 forecasts. Hold rating maintained.

Turnaround in full swing

Intelligent Monitoring Group
3:27pm
February 27, 2025
The result was robust with EBITDA +23% YoY and NPATA +41%. Both Australia and NZ delivered organic revenue growth of +6% YoY and +4%, respectively. The company expects this growth to accelerate materially given recent contract wins in ADT Australia with large enterprise customers. Guidance has been re-affirmed for >$38m EBITDA excluding FY25 acquisitions, implying organic earnings growth of at least +24% HoH. We upgrade our EBITDA forecasts to align with new guidance (>$40m including acquisitions). We forecast FY25 and FY26 EPSA growth of +34% and +51%, respectively. IMB is now trading on 5x FY26 PE. This is too cheap given the growth outlook, cash generation potential ($23m tax credits and $7-8m annual interest savings from the re-fi) and balance sheet capacity (1.4x leverage).

Strap yourself for an exciting 2025

Imricor Medical Systems
3:27pm
February 27, 2025
IMR posted its FY24 result which was in line with our forecast on an underlying basis (albeit lower sales were offset by lower costs). IMR finished the period with US$15.7m in cash, a comfortable position to drive operations forward over the coming quarters. FY25 is setting up to be an exciting year with a number of key catalysts to drive investor interest: (first ventricular tachycardia procedure (European trial); Northstar mapping approval (Europe and US); and approval for atrial flutter (in the US). We have reviewed our forecasts revising down FY25/26 by ~10% and upgrading FY27 by 34% reflecting growing sales momentum as more sites come on board and procedures are performed. As a result our DCF valuation has increased to A$2.18 (was A$1.51). Speculative buy recommendation maintained.

JAWS to crack a smile

Mach7 Technologies
3:27pm
February 27, 2025
Stronger result than expected, with better cost controls a positive surprise in the midst of continued investment in people, processes, and tools to drive longer-term operational efficiencies and product offerings. With M7T sitting on the cusp of OpEx coverage purely through subscription revenues, we see the risk/reward opportunity as continuing to improve. Minor changes to our forecasts see the valuation increase modestly to A$1.37 (from A$1.36). We continue to see significant upside potential in the name.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more